The 3rd China Conference on Individualized Treatment of Lung Cancer-ACTL Targeted Anti-tumor Immunotherapy

On March 16, 2013, in the early spring morning, the cold in Beijing had not disappeared. Domestic experts and scholars in the field of lung cancer in the conference hall of the Hilton Hotel have already begun their morning academic exchanges.

Equipped with the academic conference platform of the "3rd China Lung Cancer Individualized Treatment Conference (LCpt 2013)", Shenzhen Yishi Kangning Biotechnology Co., Ltd. invited experts from all walks of life in the field of lung cancer to gather in Beijing to participate in the title of "ACTL Cell Lecture on Anti-Lung Cancer Targeted Immunotherapy.

President Shi Yuankai of the Cancer Hospital of the Chinese Academy of Medical Sciences said that it was the first time in his memory to hold top satellite conferences, breakfast meetings or morning academic reports on cell therapy and immunotherapy in related fields. , I hope that this morning’s meeting will give participants new perspectives and new ideas, new understanding of tumor genes and somatic cell therapy, so that our doctors can benefit from it. Professor Liu Yong has been engaged in research in this area for many years and has accumulated a lot of experience. He is very clear about the global progress in this field. He hopes that through his report, everyone will have more understanding of tumor-targeted cell therapy, and share with Professor Liu Yong. The treatment experience, international progress and achievements of Shenzhen Yishi Kangning in this field. "

Professor Liu Yong systematically reported the application progress of targeted immune cell therapy represented by ACTL in anti-lung cancer from the principle and technical process of ACTL technology, combined with clinical applications at home and abroad.

Professor Liu Yong said that in December 2012, the American "Science" magazine listed "cancer immunotherapy" as one of the six most noteworthy scientific fields in 2013. The New England Journal of Medicine in the United States stated that cancer treatment has evolved into "surgery, Chemotherapy, radiotherapy and biological immunotherapy" quadrupled situation. In recent years, targeted cell therapy for tumors has developed rapidly in Europe, America and China. This year’s latest ASCO conference will also have a lot of targeted cell therapy articles and reports. I believe this development will occur in the next few years. The momentum will continue and increase.

Dean Shi commented that tumor immune cell therapy has received a lot of attention in recent years and is constantly exploring. This field has been extremely active in the past two years. Any new therapies and treatment methods need to be continuously explored after they appear, and they are continuously confirmed by clinical treatment and safety. After years of exploration of cell therapy, more and more people are interested, and the goal becomes clearer and clearer, that is, what kind of treatment is considered clinically acceptable, or cell therapy that meets clinical standards.

Dean Shi finally concluded that of course, cell therapy is still in its infancy, and is still in the process of forging ahead. We also look forward to the joint efforts of our clinical, basic research and translational research experts to make our future cell therapy, especially It is targeted cell therapy that brings greater benefits to our patients. It is hoped that through continuous efforts, we will find a standard procedure for cell therapy that meets China's national conditions and also meets international standards to benefit our Chinese cancer patients. Finally, thanks again to Professor Liu Yong for his wonderful report, which allows us to understand the latest progress in tumor treatment from another perspective, which will undoubtedly open up new areas for our future tumor treatment.

The meeting ended with warm applause.